(3-exo)-methyl-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine | 1187310-14-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: (3-exo)-methyl-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine
• CAS: 1187310-14-0
• 化学式: C₉H₁₈N₂
• 分子量: 154.255
• InChiKey: WOPJGCHLBFCBLZ-PSVAKVPMSA-N

物化性质

• 沸点：
  207.2±8.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.83
• 重原子数：
  11.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.27
• 氢给体数：
  1.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  tropane-3exo-yl-carbamic acid ethyl ester 在 lithium aluminium tetrahydride 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以94%的产率得到(3-exo)-methyl-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine
  参考文献：
  名称：

  2-AMINOQUINOLINES

  摘要：

  本发明涉及式I的2-氨基喹啉衍生物，其中R1、R2、R3、R4、R5、R6、A和n如规范和声明中定义，它们用作5-HT5A受体拮抗剂，它们的制造以及含有它们的药物组合物。

  公开号：

  US20090227570A1

文献信息

• QUINAZOLINE DERIVATIVE AND USE THEREOF
  申请人：Medshine Discovery Inc.

  公开号：EP3733663A1

  公开（公告）日：2020-11-04

  The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.

  本发明涉及一系列喹唑啉化合物，特别是由式（I）表示的化合物、其异构体或其药学上可接受的盐、其药物组合物，以及其作为泛 HER 酪氨酸激酶抑制剂的用途。
• Disubstituted 1, 2, 4-triazine compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10029993B2

  公开（公告）日：2018-07-24

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型二取代1,2,4-三嗪化合物或其药学上可接受的盐，该化合物具有醛固酮合成酶抑制活性，可用于预防和/或治疗与醛固酮相关的各种疾病或病症；本发明还提供了一种制备方法；本发明的用途；以及一种以本发明为活性成分的药物组合物。通式[I]的化合物： 其中 RA 是例如下式（A-1）的基团： 其中，环 A1 例如是可被取代的环烷基，RB 例如是单环环烷基、 或其药学上可接受的盐。
• Nitrogen-containing aromatic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10717731B2

  公开（公告）日：2020-07-21

  A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; RA represents a cycloalkyl group which may be substituted or the like, R1 represents an alkyl group or the like, R2 represents an alkyl group which may be substituted or the like, R3 represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.

  通式[I]所代表的化合物，其中 X 代表 N 或类似物，Y 代表 CH 或类似物；RA 代表环烷基，可被取代或类似物，R1 代表烷基或类似物，R2 代表烷基，可被取代或类似物，R3 代表氢原子或烷基，或其药学上可接受的盐，对醛固酮合成酶具有抑制活性，可用作与醛固酮相关的各种疾病或症状的预防和/或治疗剂。
• NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20170044115A1

  公开（公告）日：2017-02-16

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein R A is, for example, a group of the following formula (A-1): wherein ring A 1 is, for example, a cycloalkyl group which may be substituted, and R B is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.